Skip to main content

Table 1 Biological, cytogenetic, and molecular characteristics of HD, MDS, and AML patients

From: Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival

Patient ID Cytogenetics Molecular Gender Age (years) Risk MSCs/MNCs Cytogenetic alteration in MSCs
AML01 46,XX,t(6;9)
(p22;q34)[20]a
NPMwt
FLT3-ITD
Female 45 Highb 0.97 ND
AML02 46,XY[20] ND Male 80 Intermediate ND ND
AML03 46,XY[20] NPMmut FLT3wt Male 63 Low 1.5 ND
AML04 46,XY,inv(16)
(p13q22)[20]
NPMwt
FLT3wt
TP53wt
Male 55 Low 0.1 Negative
AML05 46,XX[20] NPMmut. FLT3wt
TP53wt
Female 63 Low ND ND
AML06 c ND NPMmut
FLT3-ITD TP53wt
Male 70 Intermediate ND ND
AML07 46,XY,t(15;17)
(q22;q22)[20]
ND Male 39 NA 0.2 Negative
AML08 46,XX[20] NPMmut FLT3-ITD/TKD Female 47 Intermediate 1.3 ND
AML09 46,XX[20] NPMmut
FLT3-ITD
Female 61 Intermediate 0.7 ND
AML10 47,XY,+ 8[20] NPMwt FLT3wt Male 68 Intermediate ND ND
AML11 46,XY[20] NPMmut
FLT3-ITD TP53wt
Male 73 Intermediate ND ND
AML12 47,XY,+der(3)
del(3)(p11),
t(10;11;19) (p12;q23;q13)[20]
NPMwt FLT3wt Male 17 High ND Negative
AML13 44,XX,+der(3)
t(3;20)(p12;p11),del(5)(q13q33),
−7,–13,t(13;20)
(q12;p11),
−17,der(21)
t(17;21)
(q11;q22),
+mar[14]/
45,XX,t(1;16)
(q12;q11),del(5)
(q13q33),del(6)
(q21q25),
− 7,add(22)(q13)[6]
NPMwt
FLT3wt
TP53mut
Female 60 High 0.3 ND
AML14 46,XX,t(16;16)
(p13;q22)[20]
NPMwt. FLT3wt
TP53wt
Female 46 Low ND ND
AML15 46,XY,t(6;11)
(q27;q23)[20]
NPMwt FLT3wt
TP53wt
Male 19 High 5.6 ND
AML16 46,XY,inv(16)
(p13q22)[18]/
47,XY,inv(16)
(p13q22),+ 22[2]
NPMwt
FLT3wt
TP53wt
Male 26 Low ND ND
AML17 46,XX,t(9;11)
(p22;q23) [20]
NPMwt
FLT3wt
Female 55 Intermediate 0.1 ND
AML18 47,XX,+X,
add(7)(q34)[19]/
47,XX,+X[1]
ND Female 72 Intermediate ND ND
AML19 46,XX[20] FLT3-ITD Female 61 High 6.9 ND
AML20 46,XX[20] FLT3-ITD Female 73 High 0.5 ND
AML21 47,XX,del(5)
(q22q33),+ 8[20]
ND Female 62 High ND ND
AML22 46,XY[20] FLT3-ITD Male 79 High 6.4 ND
AML23 46,XX[20] NPMmut FLT3-TKD Female 76 Low 5.6 ND
AML24 46,XX,der(4)
t(1;4)(q32;q31)
[20]
NPMwt FLT3wt
TP53wt
Female 55 Intermediate 3.7 ND
AML25 46,XY[20] NPMwt FLT3-ITD TP53wt Male 31 Intermediate ND ND
AML26 ND NPMwt
FLT3wt
TP53wt
Male 57 NA 0.5 ND
AML27 ND NPMmut
FLT3wt
TP53wt
Male 59 Low ND ND
AML28 46,XY,–7,+ 21[20] NPMwt
FLT3wt
TP53wt
Male 74 High ND ND
AML29 46,XX[20] NPMwt FLT3wt TP53wt Male 69 Intermediate ND ND
AML30 47,XY,inv(16)
(p13q22),+ 8[14]/46,XY,inv.(16) (p13q2)[6]
NPMwt
FLT3wt TP53wt
Male 56 Low ND ND
AML31 46,XY,t(6;9)
(p22;q34)[20]
NPMwt
FLT3-ITD
Male 75 Intermediate 3.2 ND
AML32 ND ND Female 71 ND ND ND
MDS1 46,XX[20]   Female 79 Low/intermediated 0.8 ND
MDS3 46,XY[20]   Male 62 Int2/High ND ND
MDS4 46,XY[20]   Male 78 Int1/Low 0.5 ND
MDS5 46,XY[20]   Male 86 Low/Low 3.3 ND
MDS6 46,XX[20]   Female 61 High/High 2.7 ND
MDS9 46,XY[20]   Male 79 Low/Low 1.2 ND
MDS11 46,XY,del(20)
(q11q13)[20]
  Male 53 Int1/intermediate ND ND
MDS12 71–74,XXX,
+der(2)t(2;17)
(p11;p12),
del(5)(q13q33), +der(5)del(5)
(q13q33),
−7[5]/46,XX[5]
  Female 73 High/high 6.7 Negative
MDS15 46,XX,del(5)
(q13q33)[5]/
46,XX,
del(5)(q13q33),
del(11)(q21q25)
[3]
  Female 76 Int1/Low 5.6 ND
MDS16 46,XY[20]   Male 80 Low/low 2.6 ND
MDS17 46,XY[20]   Male 68 High/very high 6 ND
MDS18 46,XY[20]   Male 66 Low/low 8.3 ND
MDS21 46,XY[20]   Male 78 Low/low ND ND
MDS22 46,XY[30]e   Male 61 Low/low 4.4 ND
MDS24 46,XX[20]   Female 83 Low/low 2.5 ND
MDS25 46,XX,del(20)
(q11q13)[20]
  Female 81 Low/low ND ND
MDS26 46,XY[20]   Male 54 Low/low 8.9 ND
MDS32 46,XX[20]   Female 67 Low/low 2.5 ND
MDS33 ND   Male 76 Int1/high 3.6 ND
MDS34 46,XY[20]   Male 90 Int1/low 3.5 ND
MDS35 46,XX[20]   Female 83 Low/low 2.5 ND
MDS36 47,XY,+ 8[20]   Male 82 Int2/very high 1.8 ND
MDS38 46,X,idic(X)
(q13)[16]/45,X,
–X[2]/47,X,
del(X)(q13),
+idic(X)(q13)
[1]/47,del(X) (q13),idic(X)
(q13) + idic(X)
(q13)[1]
  Female 86 Int1/low 1.1 ND
MDS39 46,XY[20]   Male 87 Int1/intermediate ND ND
MDS43 49,XY,+ 1,del(5)
(q13q33),
+der(5)del(5)
(q13q33),
+ 11[18]/47XY,
del(5)(q13q33),
+der(5)del(5)
(q13q33)[1]/
46XY,del(5)
(q13q33)[1]
  Male 79 Int2/high ND Negative
MDS45 46,XY,del(13)
(q12q14)[3]/
46,XY[17]
  Male 65 High/very high ND Negative
HD01 46,XY Male 22 ND ND
HD02 46,XY Male 19 ND ND
HD03 46,XY Male 43 8.4 ND
HD04 46,XY Male 44 2.2 ND
HD05 46,XY Male 32 5.4 ND
HD06 46,XY Male 41 2 ND
HD07 46,XX Female 62 0.5 ND
HD08 46,XY Male 60 14.3 ND
HD09 46,XX Female 43 9.4 ND
HD10 46,XX Female 52 7 ND
HD11 46,XY Male 22 11.2 ND
HD12 46,XY Male 38 ND ND
  1. AML acute myeloid leukemia, HD healthy donor, MDS myelodysplastic syndrome, MNC mononuclear seeded cell, MSC mesenchymal stromal cell, ND not determined, int1 intermediate 1 risk, int2 intermediate 2 risk
  2. aKaryotypes described according to the International System for Human Cytogenetic Nomenclature (ISCN 2016) [53, 54]
  3. bRisk evaluation following ELN 2017 [55]
  4. cPatients in which MSCs were not isolated are indicated in italics
  5. dRisk evaluation following IPSS/IPSS-R [56, 57]
  6. eCEP 8 spectrum orange DNA probe shows 3 signals in 4% of interphase nuclei